ContraVir制药公司将出席生物技术展2018年

StephenW

ContraVir Pharmaceuticals to Present at Biotech Showcase 2018
By Sarah Thompson , in PR PR California on January 2, 2018 .

EDISON, N.J., Jan. 02, 2018 — ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Biotech Showcase Conference 2018 to be held January 8-10, 2018 at the Hilton San Francisco Union Square.
James Sapirstein, Chief Executive Officer of ContraVir, will provide an overview on the company’s business during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.Presentation details are as follows:About ContraVir PharmaceuticalsContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The Company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™, designed to deliver high intrahepatic concentrations of TFV while minimizing off-target effects caused by high levels of circulating TFV, recently completed a Phase 2a trial. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg). For more information visit www.contravir.com.For further information, please contact:Sharen Pyatetskaya
Director of Investor Relations
[email protected]; (732) 902-4028

StephenW

ContraVir制药公司将出席生物技术展2018年
2018年1月2日在加利福尼亚州PR PR的Sarah Thompson。

新泽西州艾迪逊，2018年1月2日 - 专注于抗病毒药物开发和商业化的生物制药公司ContraVir制药公司（纳斯达克股票代码：CTRV）今天宣布将参加2018年生物技术展示会2018年1月8 - 10日在旧金山联合广场希尔顿酒店举行。
ContraVir首席执行官詹姆斯·萨皮尔斯坦（James Sapirstein）将在演讲期间对公司业务进行概述，并将与参加会议的投资者一起参加一对一会议。演讲详情如下： ContraVir PharmaceuticalsContraVir是一家生物制药公司，专注于针对性抗病毒治疗的开发和商业化，并专注于开发乙肝病毒（HBV）的潜在治愈性治疗。公司正在开发两种具有互补作用机制的新型抗HBV化合物。 TXL™，旨在提供高肝内浓度的TFV，同时最大限度地减少高水平的循环TFV造成的脱靶效应，最近完成了2a期试验。另一种抗HBV化合物CRV431是下一代亲环素抑制剂，具有独特的结构，增加了其对HBV的效力和选择性指数。迄今为止，体外和体内研究证明CRV431减少了HBV DNA和其他病毒蛋白，包括表面抗原（HBsAg）。欲了解更多信息，请访问www.contravir.com。欲了解更多信息，请联系：Sharen Pyatetskaya
投资者关系总监
[email protected]; （732）902-4028

windu

这个公司的进度有点慢了

StephenW

回复 windu 的帖子

TXL 必须证明相同TAF或更好。
因此CRV431作为联合药物是重要的.